Dr. Frits van Rhee of UAMS discusses Total Therapy, his approach to address high-risk patient needs, and the importance genetic and imaging tests and how these pinpoint prognosis and best treatment path options

Dr. Shaji Kumar of the Mayo Clinic discusses the road to personalized myeloma treatment and three approaches we can take today before targeted treatments become a clinic reality

Dr. Sergio Giralt of Memorial Sloan-Kettering discusses the role of transplant, how transplant side effects (including host vs. graft) are being minimized and how all roads to a cure lead through complete remission

Dr. Craig Crews of the Crews Laboratory at Yale University describes his discovery and development of carfilzomib (Kyprolis) and what it takes to get a new drug across the

Dr. James R. Berenson discusses his use of myeloma therapies in a variety of combinations to target myeloma but to also address quality of life issues

Dr. Bensinger discusses a wide variety of new approaches to treatment including monoclonal antibody studies, new oral proteasome inhibitor studies, combinations with and without transplants, and the pros and cons of allo vs. auto transplantation

Dr. Benson describes how immunotherapy and NK cells work, and why most cancers are genetic or molecular diseases and not anatomical diseases

Dr. Robert A. Kyle discusses the history of myeloma innovation and the key elements needed to drive towards a cure

Dr. C. Ola Landgren discusses the importance and availability of new, more accurate diagnostic testing, and his detailed work in MGUS and smoldering myeloma